Skip to main content
main-content

Latest news

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

DECLARE analyses show dapagliflozin benefits for reduced ejection fraction, prior MI subgroups

Heartbeat

Further analysis of the DECLARE-TIMI 58 trial shows dapagliflozin to be of particular benefit for patients who have previous myocardial infarction or heart failure with reduced ejection fraction.

Adding second diabetes medication better than switching in face of poor response

Addition

Adding an additional glucose-lowering medication is better than switching to a different one in people with type 2 diabetes, even if the original seemed to have little or no effect, shows an analysis from the MASTERMIND consortium.

Latest headlines

19-03-2019 | Glycemic control | News

Benefits of full target monitoring shown in type 2 diabetes

Full monitoring of biomedical and lifestyle-related diabetes target indicators is associated with significantly lower glycated hemoglobin levels than incomplete monitoring among people with type 2 diabetes in a care group setting, say researchers.

17-03-2019 | Canagliflozin | News

Canagliflozin may reduce HF events irrespective of ejection fraction

A post-hoc analysis of the CANVAS trial suggests that treatment with the sodium-glucose cotransporter 2 inhibitor canagliflozin reduces the risk for heart failure events regardless of whether patients have preserved or reduced ejection fraction.

15-03-2019 | Medication adherence | News

Targeted insulin-adherence intervention may improve glycemic control

Targeting specific populations of individuals with type 2 diabetes for intensive interventions to optimize their insulin use may result in better glycemic control than an untargeted approach, findings from the TARGIT-Diabetes trial suggest.

Features and expert interviews

19-02-2019 | Artificial pancreas systems | Feature | Article

What’s all the fuss about the DIY artificial pancreas?

DIY closed-loop insulin delivery has provoked controversy within the diabetes community, raising questions around patient empowerment, safety and liability, and whether the regulatory process remains fit for purpose in a technological age. medwireNews takes a look at the issues.

14-12-2018 | Risk factors | Feature | Article

Sleep duration: Waking up to a major metabolic risk factor

The effect of sleep duration on glucose regulation and cardiometabolic risk is becoming an increasingly high-profile issue. medwireNews takes a look at the latest evidence, which shows the gravity of the problem but also offers some solutions.

16-11-2018 | Dapagliflozin | Feature | Video

Researcher comment: DECLARE-TIMI 58

DECLARE-TIMI 58 steering committee member John Wilding talks us through the trial's findings (5:49).

image credits